Lupin on Wednesday said it has received approval from the U.S. FDA for Formoterol Fumarate Inhalation Solution, used in treating symptoms of chronic obstructive pulmonary disease.
The company has received approval from the U.S. Food and Drug Administration for the product which is a generic version of Mylan Specialty's Perforomist Inhalation Solution, the Mumbai-based drug maker said in a statement.
As per IQVIA MAT June 2022 data, the medication had annual sales of around $282 million in the U.S. market.
Shares of Lupin ended 2.55% down at Rs 677.65 apiece on the BSE on Wednesday.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
